Welcome to our dedicated page for Nervgen Pharma SEC filings (Ticker: NGENF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NervGen Pharma Corp. filings document a Canadian clinical-stage biotechnology issuer furnishing U.S. reports as a foreign issuer. The record includes Form 6-K current reports, material change reports, and incorporation by reference into the company’s MJDS Form F-10 registration statement.
The company’s SEC disclosures cover executive appointments and resignations, employment agreements, stock option grants, board oversight, subsidiary employment arrangements through NervGen US Inc., and capital-market registration matters. These filings also provide formal records tied to governance, compensation, equity awards, and the company’s U.S. public reporting framework.
NervGen Pharma reports new independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study showing a statistically significant treatment effect of NVG-291 versus placebo on a multivariate measure of gait quality in people with chronic tetraplegia.
The analyses, performed by AI movement specialist Newton Tech and independently verified by a computational biomedicine department, assessed coordination, mechanical effort and postural stability, which are described as hallmarks of genuine neural recovery rather than compensation. Participants were 1–10 years post–spinal cord injury, with a mean of 3.5 years.
NervGen states these results extend previously reported clinical improvements and support advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia, which is planned to start in mid-2026 following an earlier End-of-Phase 2 FDA meeting and ongoing regulatory dialogue.
NervGen Pharma reports new independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study showing a statistically significant treatment effect of NVG-291 versus placebo on a multivariate measure of gait quality in people with chronic tetraplegia.
The analyses, performed by AI movement specialist Newton Tech and independently verified by a computational biomedicine department, assessed coordination, mechanical effort and postural stability, which are described as hallmarks of genuine neural recovery rather than compensation. Participants were 1–10 years post–spinal cord injury, with a mean of 3.5 years.
NervGen states these results extend previously reported clinical improvements and support advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia, which is planned to start in mid-2026 following an earlier End-of-Phase 2 FDA meeting and ongoing regulatory dialogue.
NervGen Pharma Corp. has priced an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The securities are priced at US$2.50 per common share and accompanying warrant, for expected gross proceeds of about US$60.0 million.
Each warrant has an exercise price of US$3.68 per common share, is immediately exercisable, and will expire five years from issuance. All securities are being sold by NervGen, which plans to use the net proceeds, along with existing cash, to advance its lead drug candidate NVG-291 through clinical studies and for general corporate and working capital needs.
NervGen Pharma Corp. has priced an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The securities are priced at US$2.50 per common share and accompanying warrant, for expected gross proceeds of about US$60.0 million.
Each warrant has an exercise price of US$3.68 per common share, is immediately exercisable, and will expire five years from issuance. All securities are being sold by NervGen, which plans to use the net proceeds, along with existing cash, to advance its lead drug candidate NVG-291 through clinical studies and for general corporate and working capital needs.
NervGen Pharma reported first quarter 2026 results and highlighted progress toward its RESTORE registrational study of NVG-291 in chronic tetraplegia. The company achieved FDA alignment on RESTORE’s study parameters and is focusing on initiating the trial in mid-2026 while activating study sites and expanding senior leadership.
As of March 31, 2026, NervGen held $16.6 million in cash and investments. R&D expenses were $4.9 million, up from $3.1 million a year earlier, and G&A expenses were $2.7 million versus $2.9 million in 2025. Net loss narrowed to $1.7 million, driven mainly by a $5.7 million non-cash unrealized gain on a warrant derivative.
The company’s lead candidate NVG-291, a subcutaneous neuroreparative peptide targeting the CSPG-PTPσ pathway, has FDA Fast Track and EMA Orphan Drug designations for spinal cord injury. NervGen is also developing next-generation candidate NVG-300 and evaluating additional neurotraumatic and neurologic indications.
NervGen Pharma reported first quarter 2026 results and highlighted progress toward its RESTORE registrational study of NVG-291 in chronic tetraplegia. The company achieved FDA alignment on RESTORE’s study parameters and is focusing on initiating the trial in mid-2026 while activating study sites and expanding senior leadership.
As of March 31, 2026, NervGen held $16.6 million in cash and investments. R&D expenses were $4.9 million, up from $3.1 million a year earlier, and G&A expenses were $2.7 million versus $2.9 million in 2025. Net loss narrowed to $1.7 million, driven mainly by a $5.7 million non-cash unrealized gain on a warrant derivative.
The company’s lead candidate NVG-291, a subcutaneous neuroreparative peptide targeting the CSPG-PTPσ pathway, has FDA Fast Track and EMA Orphan Drug designations for spinal cord injury. NervGen is also developing next-generation candidate NVG-300 and evaluating additional neurotraumatic and neurologic indications.
NervGen Pharma filed a Form 6-K with unaudited IFRS results for the three months ended March 31, 2026. The company reported a net loss of $1,675,549, or $0.02 basic loss per share, compared with a loss of $3,948,192 a year earlier, mainly due to a larger non‑cash gain on its warrant derivative.
Research and development expenses rose to $4,863,626 and general and administrative expenses were $2,667,952. Cash and cash equivalents were $16,559,056 with total assets of $20,765,547 and total liabilities of $15,223,975. Management states there is material uncertainty about the company’s ability to continue as a going concern, noting that existing cash is expected to fund operations only through the second quarter of 2026 and that additional financing is required to support planned Phase 3 trials of NVG‑291 and other programs.
NervGen Pharma filed a Form 6-K with unaudited IFRS results for the three months ended March 31, 2026. The company reported a net loss of $1,675,549, or $0.02 basic loss per share, compared with a loss of $3,948,192 a year earlier, mainly due to a larger non‑cash gain on its warrant derivative.
Research and development expenses rose to $4,863,626 and general and administrative expenses were $2,667,952. Cash and cash equivalents were $16,559,056 with total assets of $20,765,547 and total liabilities of $15,223,975. Management states there is material uncertainty about the company’s ability to continue as a going concern, noting that existing cash is expected to fund operations only through the second quarter of 2026 and that additional financing is required to support planned Phase 3 trials of NVG‑291 and other programs.
NervGen Pharma Corp. appointed Keith Vendola, MD, MBA as Chief Financial Officer, effective immediately. Under his employment agreement, he will receive an annual base salary of $515,000 and be eligible for an annual cash bonus of up to 40% of salary, subject to Board discretion.
As part of his package, the Board granted Dr. Vendola options to purchase 812,002 common shares at an exercise price of $3.92 per share, vesting in three equal annual installments over three years and expiring ten years after grant. These options were issued under NervGen’s new 2026 Equity Incentive Plan.
At the recent annual meeting, shareholders approved an amendment to the Company’s Articles and adopted the 2026 Equity Incentive Plan, alongside amendments to the existing stock option plan and the routine re-appointment of KPMG as auditor and election of eight directors. The 6-K and key exhibits are incorporated by reference into NervGen’s Form F-10 shelf registration.
NervGen Pharma Corp. appointed Keith Vendola, MD, MBA as Chief Financial Officer, effective immediately. Under his employment agreement, he will receive an annual base salary of $515,000 and be eligible for an annual cash bonus of up to 40% of salary, subject to Board discretion.
As part of his package, the Board granted Dr. Vendola options to purchase 812,002 common shares at an exercise price of $3.92 per share, vesting in three equal annual installments over three years and expiring ten years after grant. These options were issued under NervGen’s new 2026 Equity Incentive Plan.
At the recent annual meeting, shareholders approved an amendment to the Company’s Articles and adopted the 2026 Equity Incentive Plan, alongside amendments to the existing stock option plan and the routine re-appointment of KPMG as auditor and election of eight directors. The 6-K and key exhibits are incorporated by reference into NervGen’s Form F-10 shelf registration.
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.
NervGen Pharma Corp. reported a planned leadership change in its finance function. Chief Financial Officer and Secretary William J. Adams, who also serves as Principal Financial and Accounting Officer, has resigned due to his retirement, effective March 15, 2026. The company states that his resignation is not related to any disagreement with management or the board.
Adams will provide transitional services through June 15, 2026 and will receive one-third of his current base salary during this period, along with an extension of the expiration date of his vested stock awards under existing equity award agreements. The board has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective on the same date Adams’ resignation becomes effective. This report is also incorporated by reference into NervGen’s existing Form F-10 registration statement.
NervGen Pharma Corp. reported a planned leadership change in its finance function. Chief Financial Officer and Secretary William J. Adams, who also serves as Principal Financial and Accounting Officer, has resigned due to his retirement, effective March 15, 2026. The company states that his resignation is not related to any disagreement with management or the board.
Adams will provide transitional services through June 15, 2026 and will receive one-third of his current base salary during this period, along with an extension of the expiration date of his vested stock awards under existing equity award agreements. The board has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective on the same date Adams’ resignation becomes effective. This report is also incorporated by reference into NervGen’s existing Form F-10 registration statement.
NervGen Pharma Corp. has appointed Dr. Adam Rogers as its Chief Executive Officer and President, effective immediately, after he served as interim CEO and Board Chair. He will continue as Chairperson of the Board.
Under his new employment agreement with a U.S. subsidiary, Dr. Rogers will receive a $350,000 annual base salary and be eligible for an annual bonus of up to 30% of salary. He was granted options to purchase 717,891 common shares, split between options priced at $5.06 and $5.57 per share, vesting over four years. The Board also agreed to grant an additional 1,146,108 performance-based options, plus 37,784 fully vested shares and 617,135 performance-based restricted stock units, subject to equity plan approvals.
The agreement includes severance and change-of-control protections, providing salary continuation, COBRA benefits, bonus eligibility and equity vesting acceleration in certain terminations, with enhanced vesting if a qualifying termination occurs around a change of control.
NervGen Pharma Corp. has appointed Dr. Adam Rogers as its Chief Executive Officer and President, effective immediately, after he served as interim CEO and Board Chair. He will continue as Chairperson of the Board.
Under his new employment agreement with a U.S. subsidiary, Dr. Rogers will receive a $350,000 annual base salary and be eligible for an annual bonus of up to 30% of salary. He was granted options to purchase 717,891 common shares, split between options priced at $5.06 and $5.57 per share, vesting over four years. The Board also agreed to grant an additional 1,146,108 performance-based options, plus 37,784 fully vested shares and 617,135 performance-based restricted stock units, subject to equity plan approvals.
The agreement includes severance and change-of-control protections, providing salary continuation, COBRA benefits, bonus eligibility and equity vesting acceleration in certain terminations, with enhanced vesting if a qualifying termination occurs around a change of control.
NervGen Pharma Corp. submitted a Form 6-K as a foreign private issuer for January 2026. The company confirms it files annual reports under Form 40-F, which is the standard for certain Canadian issuers.
Exhibit 99.1, a Material Change Report dated January 8, 2026, is included with this submission and is incorporated by reference into NervGen’s Form F-10 registration statement (File No. 333-292197). The report is signed on behalf of the company by Chief Financial Officer William J. Adams.